Upregulated microRNA-146a expression induced by granulocyte colony-stimulating factor enhanced low-dosage chemotherapy response in aged acute myeloid leukemia patients

Li, Xin; Xu, Lan; Sheng, Xianfu; Cai, Jianting; Liu, Jia; Yin, Tingyu; Xiao, Fei; Chen, Fangyuan

doi:10.1016/j.exphem.2018.09.002

Cited by 7 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Higher levels of miR-146a-5p in serum and plasma have been associated with worse response to platinum-based treatment in lung cancer [ 61 , 62 ], Imatinib therapy in patients with chronic myeloid leukemia (CML) [ 63 ], hormone [ 64 ] and radio [ 65 ] therapy in prostate cancer. In contrast, in acute myeloid leukemia (AML), high miR-146a-5p expression and/or upregulation of this miRNA during granulocyte-colony stimulating factor ( G-CSF ) priming chemotherapy was predictive of better clinical outcomes [ 66 ]. Similarly, advanced non-small cell lung cancer (NSCLC) patients with low serum exosomal miR-146a-5p levels had higher recurrence rates than those with high levels, suggesting that miR-146a-5p increased the chemosensitivity of NSCLC to cisplatin [ 67 ].…”

Section: Discussionmentioning

confidence: 99%

Circulating Small EVs miRNAs as Predictors of Pathological Response to Neo-Adjuvant Therapy in Breast Cancer Patients

Baldasici

Bălăcescu

Cruceriu

et al. 2022

IJMS

View full text Add to dashboard Cite

Neo-adjuvant therapy (NAT) is increasingly used in the clinic for the treatment of breast cancer (BC). Pathological response to NAT has been associated with improved patients’ survival; however, the current techniques employed for assessing the tumor response have significant limitations. Small EVs (sEVs)-encapsulated miRNAs have emerged as promising new biomarkers for diagnosis and prediction. Therefore, our study aims to explore the predictive value of these miRNAs for the pathological response to NAT in BC. By employing bioinformatic tools, we selected a set of miRNAs and evaluated their expression in plasma sEVs and BC biopsies. Twelve miRNAs were identified in sEVs, of which, miR-21-5p, 221-3p, 146a-5p and 26a-5p were significantly associated with the Miller–Payne (MP) pathological response to NAT. Moreover, miR-21-5p, 146a-5p, 26a-5p and miR-24-3p were independent as predictors of MP response to NAT. However, the expression of these miRNAs showed no correlation between sEVs and tissue samples, indicating that the mechanisms of miRNA sorting into sEVs still needs to be elucidated. Functional analysis of miRNA target genes and drug interactions revealed that candidate miRNAs and their targets, can be regulated by different NAT regimens. This evidence supports their role in governing the patients’ therapy response and highlights their potential use as prediction biomarkers.

show abstract

Section: Discussionmentioning

confidence: 99%

Circulating Small EVs miRNAs as Predictors of Pathological Response to Neo-Adjuvant Therapy in Breast Cancer Patients

Baldasici

Bălăcescu

Cruceriu

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Numerous studies have indicated that G-CSF could induce apoptosis of leukemia cells. For instance, G-CSF induces apoptosis in leukemia cells through upregulating microRNA-146a [ 32 ]. Besides, G-CSF augments cytarabine and etoposide-triggered apoptosis in leukemia cells [ 33 , 34 ].…”

Section: Discussionmentioning

confidence: 99%

Combination regimen of granulocyte colony-stimulating factor and recombinant human thrombopoietin improves the curative effect on elderly patients with leukemia through inducing pyroptosis and ferroptosis of leukemia cells

2022

View full text Add to dashboard Cite

Leukemia ranks as the one of most common causes of death from tumor. 51.4% of patients with leukemia are over 65 years old. However, the median overall survival (OS) of elderly leukemia patients is less than one year. It is urgent to explore more effective treatments for elderly patients with leukemia. Our recent prospective phase II single-arm study has revealed that combination regimen of granulocyte colony-stimulating factor (G-CSF) and recombinant human thrombopoietin (rhTPO) could improve the curative effect on elderly patients with leukemia, yet the precise mechanism remains unknown. This study demonstrated that combination of G-CSF and rhTPO showed greater effect on suppressing leukemia growth than G-CSF or rhTPO alone in vitro and in vivo. Mechanistically, G-CSF induced pyroptosis through ELANE in leukemia cells. Besides, rhTPO triggered ferroptosis by EP300 in leukemia cells. Moreover, rhTPO suppressed glutathione peroxidase 4 (GPX4) expression to induce ferroptosis through blocking the interaction between EP300 and GPX4 gene promoter via associating with EP300. In summary, this study illuminated that combination regimen of G-CSF and rhTPO improved the curative effect on elderly patients with leukemia through inducing pyroptosis and ferroptosis of leukemia cells. Therefore, our results provided a theoretical basis for combination regimen of G-CSF and rhTPO treating leukemia and potential therapeutic targets for leukemia.

show abstract

MicroRNAs: pivotal regulators in acute myeloid leukemia

Cui

Guan

2020

Ann Hematol

View full text Add to dashboard Cite

Upregulated microRNA-146a expression induced by granulocyte colony-stimulating factor enhanced low-dosage chemotherapy response in aged acute myeloid leukemia patients

Cited by 7 publications

References 31 publications

Circulating Small EVs miRNAs as Predictors of Pathological Response to Neo-Adjuvant Therapy in Breast Cancer Patients

Circulating Small EVs miRNAs as Predictors of Pathological Response to Neo-Adjuvant Therapy in Breast Cancer Patients

Combination regimen of granulocyte colony-stimulating factor and recombinant human thrombopoietin improves the curative effect on elderly patients with leukemia through inducing pyroptosis and ferroptosis of leukemia cells

MicroRNAs: pivotal regulators in acute myeloid leukemia

Contact Info

Product

Resources

About